Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > Tick Tock SBM
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1374)
•••
Comment by Pandoraon Jun 01, 2021 9:14am
178 Views
Post# 33302069

RE:RE:Tick Tock SBM

RE:RE:Tick Tock SBM
sakinny3 wrote:
Pareto8020 wrote:
Wonder if SBM still "anticipates" the achieving the below milestones during the next TWO months?  Remember when they said they were close on the animal deal before Christmas?  Well here we are going into June and still radio silence and no tangible deals, results or anything from Howie yet.  Time to produce or get out of the way - it is embarassing how bad they are at managing this company in everyway possible.   

• Finalize due diligence and agree on terms with new organization in China
• Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
• Secure non-dilutive funding through anticipated collaborations
• Finalize Tinyi agreement
• Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II


their list does not include signing new deals for 1067?


Or as Biden would call it -- maybe it's a one horse pony! :-))
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities